Recent Finacing
Recent Raise
Cullgen develops small-molecule targeted protein degraders using its proprietary uSMITE ubiquitin-mediated platform and novel E3 ligands, advancing oncology and inflammatory/autoimmune programs from preclinical to IND-stage.
